Walleye Capital’s Janux Therapeutics JANX Stock Holding History

Walleye Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$958K	Sell	62,338 -68,280	-52%	-$989K	﹤0.01%	2160
2026 Q1	$1.82M	Sell	130,618 -192,399	-60%	-$2.64M	0.01%	1548
2025 Q4	$4.46M	Buy	323,017 +287,196	+802%	+$6.75M	0.01%	1226
2025 Q3	$875K	Sell	35,821 -17,655	-33%	-$430K	﹤0.01%	2193
2025 Q2	$1.24M	Buy	53,476 +42,096	+370%	+$1.11M	﹤0.01%	1880
2025 Q1	$307K	Buy	+11,380	New	+$429K	﹤0.01%	2936
2024 Q3	–	Sell	-14,399	Closed	-$603K	–	5577
2024 Q2	$603K	Buy	+14,399	New	+$676K	﹤0.01%	3344

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Walleye Capital's JANX Position: Q2 2026 in Review

Walleye Capital reduced its Janux Therapeutics (JANX) stake by 52% in Q2 2026, selling an estimated $989K and leaving 62,338 shares worth $958K. The position accounts for ﹤0.01% of the portfolio, ranked #2160.

Walleye Capital first reported a position in JANX in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.46M in Q4 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Walleye Capital held 62,338 shares of Janux Therapeutics worth $958K as of Q2 2026.
Walleye Capital sold 68,280 Janux Therapeutics shares in Q2 2026, an estimated $989K.
Janux Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2160 holding.
Walleye Capital first reported a position in Janux Therapeutics in Q2 2024 and has held it in 7 quarters since.
Walleye Capital's Janux Therapeutics position peaked at $4.46M in Q4 2025.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.